BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Former Provectus CEO Used Company Cash for Restaurants, Cosmetic Surgery and More

  Craig Dees, CEO of Provectus treated the company as “his own personal piggy bank” by submitting hundreds of falsified records to obtain $3.2M for personal expenses

  December 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe

  Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.

  December 13, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  What You Need to Know About Immune-Onc Therapeutics

  Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.

  December 13, 2017

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  What You Need to Know About Tango Therapeutics

  Tango officially launched in 2017 and hit the ground running as a cancer drug target discovery and drug development company based on CRISPR technology.

  December 13, 2017

   · 

  5 min read

   · 

  Mark Terry
• Genetown

  Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia

  The newly issued patents are exclusively licensed to Vedanta under an agreement with the University of Tokyo and provide coverage through at least 2031.

  December 13, 2017

   · 

  4 min read
• Business

  Evotec Enters Into Research Collaboration With CRTD to Discover Novel Therapies for Retinal Diseases

  Under the terms of the collaboration, Evotec will leverage CRTD’s expertise in stem cell-based retinal disease modelling and will apply its leading induced pluripotent stem cell (“iPSC”) technology platform to identify promising drug candidates for potential clinical development.

  December 13, 2017

   · 

  5 min read
• Drug Development

  NeuroVive’s KL1333 Program Granted Orphan Drug Designation by the European Commission

  The orphan drug designation for KL1333, together with NeuroVive’s status as a micro, small and medium-sized enterprise (SME), offers NeuroVive access to free scientific advice from the EMA.

  December 13, 2017

   · 

  4 min read
• Business

  BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics

  BioLife Solutions today announced that it has executed an agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media to Iovance Biotherapeutics.

  December 13, 2017

   · 

  6 min read
• Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

  In the 29 patients evaluable for response, the investigator assessed objective response (OR) and complete response (CR) rates were 90% and 66%, respectively.

  December 13, 2017

   · 

  8 min read
• Drug Development

  MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase I Trial for the Treatment of Pancreatic, Colon and Lung Cancers

  This Phase 1 first-in-human clinical trial is an open-label, multi-center study evaluating the safety and efficacy of MVT-1075 in approximately 22 patients with CA19-9 positive malignancies in the U.S.

  December 13, 2017

   · 

  6 min read